Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review

Authors Suzanne A Ligthart, Eric P Moll van Charante, Willem A Van Gool, et al

Published 17 August 2010 Volume 2010:6 Pages 775—785


Review by Single-blind

Peer reviewer comments 3

Suzanne A Ligthart1, Eric P Moll van Charante1, Willem A Van Gool2, Edo Richard2
1Department of General Practice, 2Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Background: Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, ­hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Keywords: cardiovascular risk factors, cognitive decline, dementia, prevention

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Association between EHBP1 rs721048(A>G) polymorphism and prostate cancer susceptibility: a meta-analysis of 17 studies involving 150,678 subjects

Ao X, Liu Y, Bai XY, Qu X, Xu Z, Hu G, Chen M, Wu H

OncoTargets and Therapy 2015, 8:1671-1680

Published Date: 7 July 2015

Large bilateral foveal cysts in the inner retina of a patient treated with tamoxifen, diagnosed with Fourier-domain optical coherence tomography

Georgalas I, Paraskevopoulos T, Papaconstantinou D, Brouzas D, Koutsandrea C

Clinical Ophthalmology 2013, 7:707-709

Published Date: 10 April 2013

Effects of safflower seed extract on arterial stiffness

Katsuya Suzuki, Shigekazu Tsubaki, Masami Fujita, et al

Vascular Health and Risk Management 2010, 6:1007-1014

Published Date: 3 November 2010

Practical recommendations for treatment of hypertension in older patients

Philip A Kithas, Mark A Supiano

Vascular Health and Risk Management 2010, 6:561-569

Published Date: 29 June 2010

Use of sulodexide in patients with peripheral vascular disease

J Lasierra-Cirujeda, P Coronel, MJ Aza, et al

Journal of Blood Medicine 2010, 1:105-114

Published Date: 15 June 2010

Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo)

Marco Matteo Ciccone, Ambrogio Aquilino, Francesca Cortese, et al

Vascular Health and Risk Management 2010, 6:297-305

Published Date: 28 April 2010

Does plasmin have anticoagulant activity?

Jane Hoover-Plow

Vascular Health and Risk Management 2010, 6:199-205

Published Date: 26 March 2010

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Ajikumar V Aryangat, John E Gerich

Vascular Health and Risk Management 2010, 6:145-155

Published Date: 9 March 2010